CorMedix (CRMD) Stock Price

CorMedix Price

NASDAQ·CLOSED
7.45USD-0.07 (-0.97 %)
Market closed

Revenue has compounded at 170.8% per year over the past 12 years to 311.71 M USD. CorMedix's net margin stands at 52.3%, up from -9,207.7% several years earlier. Analysts set a median price target of 15.30 USD, implying 105.3% above the current price. Of 13 analysts, 12 rate the stock a buy — an overall Buy consensus. The stock trades about 19% above its 52-week low.

CorMedix stock price

Volume
Details

Stock Price

ⓘ

How to Read This Chart

This chart tracks the historical stock price of CorMedix over time. You can switch between daily, weekly, and monthly views and select custom time ranges — from a single day to the full available history. Use the toggle to view price changes in absolute currency terms or as a percentage change relative to the starting date.

Total Return vs. Price Return

The "Total Return" toggle includes reinvested dividends on top of the pure price movement. This is critical because dividends can account for a significant portion of long-term returns. Historically, roughly 40 % of the S&P 500's total return has come from dividends. Always compare total return when evaluating a stock's real performance against a benchmark.

Intraday Price Data

When viewing a one-day time frame, the chart displays real-time intraday price movements. This is useful for observing how CorMedix stock reacts to market openings, earnings releases, or breaking news throughout the trading session.

What to Look For

Look for long-term trends (sustained upward or downward movements over months and years), support and resistance levels (price zones where the stock repeatedly bounces or reverses), and volatility (how much the price fluctuates day to day). Comparing CorMedix's price chart to a market index like the S&P 500 can reveal whether the stock is outperforming or underperforming the broader market.

CorMedix Stock Price History
DateCorMedix Price
8/5/20267.45 USD
8/4/20267.53 USD
8/3/20267.55 USD
7/31/20267.53 USD
7/30/20267.49 USD
7/29/20267.24 USD
7/27/20267.89 USD
7/23/20268.05 USD
7/22/20267.94 USD
7/21/20268.19 USD
7/20/20267.78 USD
7/17/20268.42 USD
7/16/20268.29 USD
7/15/20268.42 USD
7/14/20268.27 USD
7/13/20268.36 USD
7/10/20268.40 USD
7/9/20268.67 USD
7/8/20268.91 USD
7/7/20268.87 USD
7/6/20268.71 USD
7/2/20268.75 USD
7/1/20268.47 USD
6/30/20267.85 USD
6/29/20267.64 USD
6/26/20267.85 USD
6/25/20267.72 USD
6/24/20268.39 USD
6/23/20268.60 USD
6/22/20268.88 USD
6/18/20268.77 USD
6/17/20268.76 USD
6/16/20268.60 USD
6/15/20268.65 USD
6/12/20268.80 USD
6/11/20268.93 USD
6/10/20268.76 USD
6/9/20268.65 USD
6/8/20268.54 USD
6/5/20268.49 USD
6/4/20268.60 USD
6/3/20268.22 USD
6/2/20268.27 USD
6/1/20268.47 USD
5/29/20268.43 USD
5/28/20268.41 USD
5/27/20268.50 USD
5/26/20268.24 USD
5/22/20268.10 USD
5/21/20267.82 USD
5/20/20267.94 USD
5/19/20267.82 USD
5/18/20267.91 USD
5/15/20267.55 USD
5/14/20267.93 USD
5/13/20267.50 USD
5/12/20267.51 USD
5/11/20267.66 USD
5/8/20267.92 USD
5/7/20267.92 USD
5/6/20268.05 USD
5/5/20267.73 USD
5/4/20267.90 USD
5/1/20267.79 USD
4/30/20267.59 USD
4/29/20267.48 USD
4/28/20267.57 USD
4/27/20267.82 USD
4/24/20267.42 USD
4/23/20267.46 USD
4/22/20267.49 USD
4/21/20267.38 USD
4/20/20267.58 USD
4/17/20267.39 USD
4/16/20267.13 USD
4/15/20267.23 USD
4/14/20267.30 USD
4/13/20267.32 USD
4/10/20267.24 USD
4/9/20267.36 USD
4/8/20267.23 USD
4/7/20267.17 USD
4/6/20267.08 USD
4/2/20267.05 USD
4/1/20267.02 USD
3/31/20266.79 USD
3/30/20266.57 USD
3/27/20266.71 USD
3/26/20266.70 USD
3/25/20266.61 USD
3/24/20266.46 USD
3/23/20266.42 USD
3/20/20266.25 USD
3/19/20266.30 USD
3/18/20266.37 USD
3/17/20266.46 USD
3/16/20266.54 USD
3/13/20266.45 USD
3/12/20266.40 USD
3/11/20266.69 USD
3/10/20266.72 USD
3/9/20266.56 USD
3/6/20266.46 USD
3/5/20266.30 USD
3/4/20267.12 USD
3/3/20266.91 USD
3/2/20267.21 USD
2/27/20267.13 USD
2/26/20267.35 USD
2/25/20267.31 USD
2/24/20267.07 USD
2/23/20267.01 USD
2/20/20267.03 USD
2/19/20267.08 USD
2/18/20267.17 USD
2/17/20267.21 USD
2/13/20267.34 USD
2/12/20267.36 USD
2/11/20267.43 USD
2/10/20267.69 USD
2/9/20267.58 USD
2/6/20267.69 USD
2/5/20267.35 USD
2/4/20267.84 USD
2/3/20268.12 USD
2/2/20268.17 USD
1/30/20267.76 USD
1/29/20268.02 USD
1/28/20267.75 USD
1/27/20267.75 USD
1/26/20267.76 USD
1/23/20267.27 USD
1/22/20267.44 USD
1/21/20267.33 USD
1/20/20266.88 USD
1/16/20266.78 USD
1/15/20267.01 USD
1/14/20267.09 USD
1/13/20267.06 USD
1/12/20267.15 USD
1/9/20267.63 USD
1/8/20267.51 USD
1/7/202611.17 USD
1/6/202611.26 USD
1/5/202612.19 USD
1/2/202612.16 USD
12/31/202511.63 USD
12/30/202512.48 USD
12/29/202512.73 USD
12/26/202512.53 USD
12/24/202512.19 USD
12/23/202511.98 USD
12/22/202512.39 USD
12/19/202512.02 USD
12/18/202511.92 USD
12/17/202511.45 USD
12/16/202511.44 USD
12/15/202511.33 USD
12/12/202511.49 USD
12/11/202511.74 USD
12/10/202511.47 USD
12/9/202511.62 USD
12/8/202511.26 USD
12/5/202510.56 USD
12/4/202510.64 USD
12/3/202510.32 USD
12/2/20259.78 USD
12/1/20259.79 USD
11/28/20259.81 USD
11/26/20259.65 USD
11/25/20259.40 USD
11/24/20259.82 USD
11/21/20259.68 USD
11/20/20259.72 USD
11/19/202510.03 USD
11/18/202510.08 USD
11/17/20259.98 USD
11/14/202511.24 USD
11/13/202511.21 USD
11/12/202511.42 USD
11/11/202511.19 USD
11/10/202511.08 USD
11/7/202510.76 USD
11/6/202510.78 USD
11/5/202511.16 USD
11/4/202511.42 USD
11/3/202511.54 USD
10/31/202511.13 USD
10/30/202511.62 USD
10/29/202511.31 USD
10/28/202511.14 USD
10/27/202511.05 USD
10/24/202511.17 USD
10/23/202511.31 USD
10/22/202511.20 USD
10/21/202511.65 USD
10/20/202512.16 USD
10/17/202510.18 USD
10/16/202510.08 USD
10/15/202510.61 USD
10/14/202510.54 USD
10/13/202510.58 USD
10/10/202510.73 USD
10/9/202511.00 USD
10/8/202511.27 USD
10/7/202511.09 USD
10/6/202511.56 USD
10/3/202511.34 USD
10/2/202511.05 USD
10/1/202511.05 USD
9/30/202511.63 USD
9/29/202511.85 USD
9/26/202511.30 USD
9/25/202511.12 USD
9/24/202511.24 USD
9/23/202511.44 USD
9/22/202511.27 USD
9/19/202511.20 USD
9/18/202511.69 USD
9/17/202511.12 USD
9/16/202511.59 USD
9/15/202512.65 USD
9/12/202512.94 USD
9/11/202513.09 USD
9/10/202512.79 USD
9/9/202513.03 USD
9/8/202512.75 USD
9/5/202512.40 USD
9/4/202512.80 USD
9/3/202513.70 USD
9/2/202514.64 USD
8/29/202514.83 USD
8/28/202514.35 USD
8/27/202514.14 USD
8/26/202513.99 USD
8/25/202513.73 USD
8/22/202513.69 USD
8/21/202513.56 USD
8/20/202513.52 USD
8/19/202513.06 USD
8/18/202513.10 USD
8/15/202512.93 USD
8/14/202512.61 USD
8/13/202512.08 USD
8/12/202511.50 USD
8/11/202510.07 USD
8/8/202510.33 USD
8/7/202510.81 USD
8/6/202511.95 USD
Access this data via the Eulerpool API
Get Free API Key

CorMedix Revenue, EBIT, Net Income

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details
Date
Revenue
EBIT
Net Income
Jan 1, 2023
0.00 USD
-48.96 M USD
-46.34 M USD
Jan 1, 2024
43.47 M USD
-22.36 M USD
-17.93 M USD
Jan 1, 2025
311.71 M USD
150.14 M USD
163.06 M USD
Jan 1, 2026 (e)
334.58 M USD
-63.80 M USD
39.71 M USD
Jan 1, 2027 (e)
285.22 M USD
-54.39 M USD
6.93 M USD
Jan 1, 2028 (e)
345.78 M USD
-65.94 M USD
33.68 M USD
Jan 1, 2029 (e)
437.54 M USD
-83.44 M USD
75.05 M USD
Jan 1, 2030 (e)
513.09 M USD
-97.85 M USD
105.58 M USD

CorMedix Income Statement, Balance Sheet, Cash Flow Statement

Last updated Aug 6, 2026, 11:08 AM
 
REVENUEM USD
REVENUE GROWTH%
GROSS MARGIN%
GROSS INCOMEM USD
EBITM USD
EBIT MARGIN%
NET INCOMEM USD
NET INCOME GROWTH%
SHARESM
201520162017201820192020202120222023202420252026e2027e2028e2029e2030e
–––––––––43.00311.00334.00285.00345.00437.00513.00
––––––––––623.267.40-14.6721.0526.6717.39
–––––––––93.0288.4288.4288.4288.4288.4288.42
275.00275.00275.00275.00275.00275.00275.00275.00275.0040.00275.00295.34252.01305.06386.41453.62
-16.00-24.00-32.00-26.00-21.00-27.00-29.00-30.00-48.00-22.00150.00-63.00-54.00-65.00-83.00-97.00
–––––––––-51.1648.23-18.86-18.95-18.84-18.99-18.91
-18.00-24.00-33.00-26.00-16.00-22.00-28.00-29.00-46.00-17.00163.0039.006.0033.0075.00105.00
-10.0033.3337.50-21.21-38.4637.5027.273.5758.62-63.04-1,058.82-76.07-84.62450.00127.2740.00
7.208.1313.3420.8825.6732.4038.1141.8657.3961.5193.9293.9293.9293.9293.9293.92
Details

Income Statement Key Figures

ⓘ

Revenue and Revenue Growth

Revenue is the starting point of every income statement — it measures the total sales CorMedix generates from its core business. Revenue growth (expressed as year-over-year percentage change) is one of the most important indicators of business momentum. Sustained growth above 10 % annually is generally considered strong, while declining revenue is a serious warning sign that demands investigation.

Gross Margin

Gross margin = (Revenue − Cost of Goods Sold) ÷ Revenue. It reveals what percentage of each dollar of revenue CorMedix retains after direct production costs. High gross margins (above 50 %) are typical of asset-light businesses like software and brands, while capital-intensive industries like manufacturing often operate below 30 %. Compare CorMedix's gross margin to industry peers and track it over time to spot improving or deteriorating pricing power.

EBIT and EBIT Margin

EBIT measures operating profit — what remains after subtracting all operating expenses (including R&D, sales, and administrative costs) from gross profit. The EBIT margin shows this as a percentage of revenue. Because it excludes interest and taxes, EBIT allows fair comparisons between companies with different debt levels and tax jurisdictions. A rising EBIT margin indicates improving operational efficiency.

Net Income and Earnings Per Share (EPS)

Net income is the company's final profit after all expenses, interest, and taxes. Dividing net income by the number of shares outstanding gives you EPS — the single most influential metric in stock valuation. Consistent EPS growth is the primary driver of long-term stock price appreciation. Always check whether EPS growth comes from genuine profit improvement or from share buybacks reducing the share count.

Shares Outstanding

The total number of shares CorMedix has issued. A declining share count (through buybacks) boosts EPS and signals management confidence. A rising share count (through stock issuance) dilutes existing shareholders. Always monitor this number alongside EPS to get the full picture of per-share value creation.

Analyst Estimates

The projected figures represent consensus estimates from professional analysts. Compare these forecasts against CorMedix's historical growth rates to assess whether expectations are realistic. A company that consistently beats consensus estimates tends to see its stock price rewarded over time, while repeated misses erode investor confidence.

CorMedix stock margins

The CorMedix margin analysis displays the gross margin, EBIT margin, as well as the profit margin of CorMedix. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for CorMedix.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details
Date
Gross margin
EBIT margin
Profit margin
Jan 1, 2021
22.00 %
-15,477.81 %
-14,774.70 %
Jan 1, 2022
94.29 %
-46,819.91 %
-45,409.90 %
Jan 1, 2023
88.46 %
- %
- %
Jan 1, 2024
92.66 %
-51.43 %
-41.24 %
Jan 1, 2025
88.46 %
48.17 %
52.31 %
Jan 1, 2026 (e)
88.46 %
-19.07 %
11.87 %
Jan 1, 2027 (e)
88.46 %
-19.07 %
2.43 %
Jan 1, 2028 (e)
88.46 %
-19.07 %
9.74 %

CorMedix Stock Revenue, EBIT, Earnings per Share

The CorMedix earnings per share therefore indicates how much revenue CorMedix has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue per Share
EBIT per share
Earnings per Share
Details
Date
Revenue per Share
EBIT per share
Earnings per Share
Jan 1, 2021
0.01 USD
-0.78 USD
-0.74 USD
Jan 1, 2022
0.00 USD
-0.73 USD
-0.71 USD
Jan 1, 2023
0.00 USD
-0.85 USD
-0.81 USD
Jan 1, 2024
0.71 USD
-0.36 USD
-0.29 USD
Jan 1, 2025
3.32 USD
1.60 USD
1.74 USD
Jan 1, 2026 (e)
4.25 USD
-0.68 USD
0.50 USD
Jan 1, 2027 (e)
3.62 USD
-0.58 USD
0.09 USD
Jan 1, 2028 (e)
4.39 USD
-0.70 USD
0.43 USD

CorMedix business model & stock analysis

CorMedix Employees

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

CorMedix Employees
Details
Date
CorMedix Employees
Jan 1, 2018
- Employees
Jan 1, 2019
- Employees
Jan 1, 2020
- Employees
Jan 1, 2021
- Employees
Jan 1, 2022
- Employees
Jan 1, 2023
- Employees
Jan 1, 2024
- Employees
Jan 1, 2025
- Employees

CorMedix Segments

CorMedix Revenue by Region

  • 3 Years

  • 5 Years

  • Max

European and Mideast operations
Details
Date
European and Mideast operations
Jan 1, 2019
274,443.00 USD
0.00 USD
Jan 1, 2020
237,025.00 USD
0.00 USD
Jan 1, 2021
0.00 USD
190,936.00 USD

CorMedix Eulerpool Fair Value

Details

Fair Value Estimate

ⓘ

What Is Fair Value?

Fair value is an estimate of what a stock is truly "worth" based on its financial fundamentals, independent of the current market price. If the calculated fair value is above the current share price, the stock may be undervalued — and vice versa. This chart shows three different fair value approaches so you can cross-check them against each other.

Earnings-Based Fair Value

Calculated by multiplying the current earnings per share (EPS) by the average historical P/E ratio over a selected multi-year period. The smoothing over several years filters out temporary spikes or dips. If this fair value exceeds the market price, it suggests the stock is cheap relative to its earning power.

Example: Fair Value (Earnings) 2022 = EPS 2022 × Average P/E 2019–2021

Revenue-Based Fair Value

Derived by multiplying revenue per share by the average historical price-to-sales ratio. This method is particularly useful for companies with volatile or temporarily depressed earnings, as revenue tends to be more stable than profits. It answers: "At what price has the market historically valued each dollar of this company's sales?"

Example: Fair Value (Revenue) 2022 = Revenue per Share 2022 × Average P/S 2019–2021

Dividend-Based Fair Value

Calculated by dividing the dividend per share by the average historical dividend yield. This approach is most relevant for mature, consistently dividend-paying companies. If the resulting fair value is higher than the current price, it implies the stock offers a better yield than its historical average.

Example: Fair Value (Dividend) 2022 = Dividend per Share 2022 ÷ Average Yield 2019–2021

How to Use This Chart

When all three fair value lines converge above the current price, it strengthens the case that the stock is undervalued. When they diverge, investigate why — it may indicate a structural shift in margins, payout policy, or growth rate. The forward estimates on the right extend the analysis using projected fundamentals, helping you assess whether the current price already reflects future growth expectations.

CorMedix historical P/E ratio, EBIT multiple, and P/S ratio

CorMedix annual returns

Details

Annual Return

ⓘ

What This Chart Shows

This chart breaks down 's total annual return into two components: price return (gains or losses from stock price movement) and dividend return (income received from dividend payments). Together, they represent the total return an investor would have earned in each calendar year.

Price Return

Price return measures the percentage change in 's stock price from January 1st to December 31st of each year. Positive bars indicate the stock appreciated; negative bars show a decline. This is the component most investors focus on, but it tells only part of the story — especially for dividend-paying stocks.

Dividend Return

Dividend return represents the income generated from dividends paid during the year, expressed as a percentage of the starting stock price. While it may seem small in any single year (typically 1–4 % for established companies), dividends compound significantly over decades and have historically contributed roughly 40 % of total stock market returns.

What to Look For

Examine how many years showed positive vs. negative returns to gauge consistency. A stock with mostly positive years and small drawdowns suggests lower risk. Also compare 's annual returns to a benchmark index — consistently outperforming the market is a hallmark of a strong investment. Pay attention to the worst years: understanding downside risk is just as important as chasing upside potential.

CorMedix shares outstanding

The number of shares of CorMedix was 93.92 M in 2025. This indicates how many shares CorMedix is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Number of stocks
Details
Date
Number of stocks
Jan 1, 2021
38.11 M Stocks
Jan 1, 2022
41.86 M Stocks
Jan 1, 2023
57.39 M Stocks
Jan 1, 2024
61.51 M Stocks
Jan 1, 2025
93.92 M Stocks
Jan 1, 2026 (e)
93.92 M Stocks
Jan 1, 2027 (e)
93.92 M Stocks
Jan 1, 2028 (e)
93.92 M Stocks

CorMedix stock splits

In CorMedix's history, there have been no stock splits.

Current CorMedix forecasts and price targets in August 2026

Analyst Price Targets 2026
Δ MOM Price Target
6.25 %
Buy
92.31 % (12)
Hold
7.69 % (1)
Sell
0.00 % (0)
12M Price Target
15.30
Last Price
7.45
Currency
USD
12M Return Potential
105.29 %
LTM Return
0 %

CorMedix Analyst Rating Actions

DateFirmActionRatingReliability
7/7/2026
RBC Capital
RBC Capital
MaintainedOutperform52
4/28/2026
RBC Capital
RBC Capital
MaintainedOutperform52
4/28/2026
Leerink Partners
Leerink Partners
MaintainedOutperform–
4/28/2026
Citizens
Citizens
MaintainedMarket Outperform–
4/27/2026
Needham
Needham
MaintainedBuy70
4/27/2026
D. Boral Capital
D. Boral Capital
MaintainedBuy–
3/5/2026
Needham
Needham
MaintainedBuy70
2/11/2026
D. Boral Capital
D. Boral Capital
MaintainedBuy–
1/23/2026
HC Wainwright & Co.
HC Wainwright & Co.
MaintainedBuy–
1/21/2026
RBC Capital
RBC Capital
MaintainedOutperform52

Eulerpool Reliability Score (0–100): measures how often a firm’s bullish or bearish calls were directionally correct three months later, blended with the average return following its calls. Every rating we record is stored permanently and scores update continuously; firms with fewer than 3 measured calls are not scored yet.

CorMedix Earnings Calls

2025

CorMedix Earnings Estimates & Surprises

DateEPS estimateEPS ActualRevenue EstimatePrice reactionQuarterly report
8/13/20260.24USD-97.53 MUSD-2026 Q2
5/14/20260.37USD-107.12 MUSD-2026 Q1
11/12/2024-0.10USD-11.06 MUSD-2024 Q3
5/13/2024-0.20USD-0.00USD-2024 Q1
3/28/2024-0.20USD--255,000.00USD-2023 Q4
11/8/2023-0.21USD-0.00USD-2023 Q3
8/9/2023-0.21USD-0.00USD-2023 Q2
11/10/2022-0.23USD-0.00USD-2022 Q3

EESG©

Eulerpool ESG Scorecard© for the CorMedix stock

25/100
4
Environment
33
Social
37
Governance
E

Environment

20
Scope 1 - Direct Emissions—
Scope 2 - Indirect emissions from purchased energy—
Scope 3 - Indirect emissions within the value chain—
Total CO₂ emissions—
CO₂ reduction strategy
Coal energy
Nuclear power
Animal experiments
Fur & Leather—
Pesticides—
Palm Oil—
Tobacco
Genetically modified organisms
Climate concept—
Sustainable forestry—
Recycling regulations
Environmentally friendly packaging
Hazardous substances
Fuel consumption and efficiency
Water consumption and efficiency
S

Social

20
Percentage of female employees—
Percentage of women in management—
Percentage of Asian employees—
Share of Asian management—
Percentage of Hispanic/Latino employees—
Hispano/Latino Management share—
Percentage of Black employees—
Black Management Share—
Percentage of white employees—
White Management Share—
Adult content
Alcohol
Weapons—
Firearms
Gambling
Military contracts
Human rights concept
Privacy concept—
Occupational health and safety
Catholic
G

Governance (Corporate Governance)

4
Environmental reporting
Stakeholder Engagement
Call Back Policies
Antitrust law

The Eulerpool ESG Scorecard© is the strictly copyrighted intellectual property of Eulerpool Research Systems. Any unauthorized use, imitation, or infringement will be actively pursued and may lead to significant legal consequences. For licenses, collaborations, or usage rights, please contact us directly via our contact form. Contact Form to us.

CorMedix shareholder structure

% Name
5.89622%
Abdalkader (Shaibatalhamd Aymen)
Abdalkader (Shaibatalhamd Aymen)
0.71596%
Palisades Investment Partners, LLC
Palisades Investment Partners, LLC
0.53376%
October Effect Ltd
October Effect Ltd
0.47374%
Royce Investment Partners
Royce Investment Partners
0.38356%
Todisco (Joseph)
Todisco (Joseph)
0.31730%
Swedbank Robur Fonder AB
Swedbank Robur Fonder AB
...

CorMedix Beneficial Ownership Filings (SEC 13D/G)

Free Float
84.8%
Float Shares
-
Shares Outstanding
-
StakeHolderFiling
19.95%
CorMedix Inc.
CorMedix Inc.
SEC ↗
10.00%
PharmaBio Development Inc.
PharmaBio Development Inc.
SEC ↗
7.94%
Deep Track Capital, LP
Deep Track Capital, LP
SEC ↗
7.50%
BlackRock, Inc.
BlackRock, Inc.
SEC ↗
6.40%
(1) BlackRock, Inc.
(1) BlackRock, Inc.
SEC ↗
5.90%
SHAIBATALHAMD AYMEN ABDALKADER
SHAIBATALHAMD AYMEN ABDALKADER
SEC ↗
5.30%
Nomura Holdings, Inc.
Nomura Holdings, Inc.
SEC ↗
5.30%
Nomura Global Financial Products, Inc.
Nomura Global Financial Products, Inc.
SEC ↗
5.15%
The Vanguard Group - 23-1945930
The Vanguard Group - 23-1945930
SEC ↗
5.00%
LINDSAY A. ROSENWALD, M.D.
LINDSAY A. ROSENWALD, M.D.
SEC ↗

CorMedix Executives and Management Board

13 members · avg. age 59 · 38 % women

JT

Mr. Joseph Todisco (49)

Chief Executive Officer, Director · since 2022

2.36 M USD

Management

EM

Ms. Erin Mistry (43)

Executive Vice President, Chief Commercial Officer

1.24 M USD
EH

Ms. Elizabeth Hurlburt (46)

Chief Operating Officer

1.14 M USD
MD

Dr. Matthew David (47)

Chief Business Officer

1.09 M USD
SB

Ms. Susan Blum

Chief Financial Officer

–
BK

Ms. Beth Kaufman (65)

Executive Vice President, Chief Legal and Compliance Officer, Corporate Secretary

–
DF

Mr. Dan Ferry

IR Contact Officer

–

Board of Directors

MK

Mr. Myron Kaplan (80)

Independent Chairman of the Board

210,564.00 USD
SL

Mr. Steven Lefkowitz (69)

Independent Director · since 2011

174,564.00 USD
JD

Ms. Janet Dillione (65)

Independent Director

159,564.00 USD
RS

Mr. Robert Stewart (57)

Independent Director

156,564.00 USD
GD

Mr. Gregory Duncan (60)

Independent Director

153,564.00 USD
AD

Dr. Alan Dunton (71)

Independent Director

153,564.00 USD

CorMedix Supply Chain

CorMedix Supply Chain

Correlation: how closely stock prices move together

Same directionNo relationOpposite
1 companies
#NameTrend
1
Wonik
Customer·Health Care Providers & Services·KR
0.54
0.39
-0.57
-0.19
0.67
0.33

Frequently asked questions about CorMedix

Analysts currently set an average price target of 16.47 USD for the CorMedix stock (median: 15.30 USD), implying +120.9 % versus the latest price. The consensus is based on 13 analyst ratings.

CorMedix Analyst Price Targets 2026

13 analysts currently rate the CorMedix stock: 12 recommend buying, 1 holding and 0 selling. For 2026, analysts expect CorMedix to generate revenue of 334.58 M USD and earnings per share of 0.42 USD.

CorMedix Analyst Price Targets 2026

Converted at the current exchange rate, the CorMedix share trades at 6.45 EUR (7.45 USD).

The CorMedix share (CRMD) is listed on 4 stock exchanges, including: NASDAQ (CRMD), Frankfurt (19KA.F), München (19KA.MU).

No history available for CorMedix.

The expected revenue of CorMedix is 334.58 M USD. This figure is based on current financial data and reflects the company's business performance.

The expected profit of CorMedix is 39.71 M USD. The net profit reflects the company's profitability after deducting all expenses.

The price-to-earnings ratio (P/E) of CorMedix is currently 17.63. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the CorMedix stock.

The price-to-sales ratio (P/S) of CorMedix is currently 2.09. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the CorMedix stock.

The Eulerpool Quality Score for CorMedix is 7/10.

The ISIN of CorMedix is US21900C3088. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.

The WKN of CorMedix is A2PF3G. The WKN (Wertpapierkennnummer) is a six-digit German security identification number.

The ticker of CorMedix is CRMD. The ticker symbol is used to trade CorMedix shares on the stock exchange.

CorMedix paid dividends every year for the past 0 years.

CorMedix is assigned to the 'Health' sector.

The dividends of CorMedix are distributed in USD.

All fundamentals and in-depth analysis of CorMedix

Our stock analysis for CorMedix stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of CorMedix. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.

CorMedix Stock
CorMedix Revenue→
CorMedix Stock
CorMedix Net Income→
CorMedix Stock
CorMedix P/E→
CorMedix Stock
CorMedix P/S→
CorMedix Stock
CorMedix EBIT→
CorMedix Stock
CorMedix Dividend→
CorMedix Stock
CorMedix Directors Dealings→
CorMedix Stock
CorMedix Stocks→
CorMedix Stock
CorMedix Market capitalization→
CorMedix Stock
CorMedix Debt→
CorMedix Stock
CorMedix Liabilities→
CorMedix Stock
CorMedix Equity→
CorMedix Stock
CorMedix AAQS→
CorMedix Stock
CorMedix Employees→
CorMedix Stock
CorMedix ROE→
CorMedix Stock
CorMedix ROA→
CorMedix Stock
CorMedix ROCE→
CorMedix Stock
CorMedix News→
CorMedix Stock
CorMedix Analyst Price Targets→

Health Stocks

Correlate EnergyCorline BiomedicalCorVelCorix BioscienceCorvus PharmaceuticalsCorestemchemonCosmo Bio CoCorentec CoCosmo PharmaceuticalsCoreLine Soft CoCosmos HealthCordlife GroupAll Stocks A–Z →